Your browser doesn't support javascript.
loading
Neoadjuvant treatment strategies for HER2-positive breast cancer: cost-effectiveness and quality of life outcomes.
Hassett, M J; Li, H; Burstein, H J; Punglia, R S.
Afiliación
  • Hassett MJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Li H; Yale School of Public Health, New Haven, CT, USA.
  • Burstein HJ; Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.
  • Punglia RS; Department of Radiation Oncology, Dana-Farber Cancer Institute/Brigham and Women's Hospital, Harvard Medical School, 450 Brookline Avenue, Boston, MA, 02115, USA. rpunglia@partners.org.
Breast Cancer Res Treat ; 181(1): 43-51, 2020 May.
Article en En | MEDLINE | ID: mdl-32185586
Asunto(s)
Palabras clave
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos
Texto completo
Imprimir
XML
PubMed Links
Buscar en Google

Texto completo: 1 Banco de datos: MEDLINE Asunto principal: Neoplasias de la Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Tipo de estudio: Health_economic_evaluation / Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Female / Humans / Middle aged Idioma: En Revista: Breast Cancer Res Treat Año: 2020 Tipo del documento: Article País de afiliación: Estados Unidos